Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUICKENED: Quercetin for Cardio-Skeletal Muscle Health
NCT04258410Phase 4Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 4, randomised, double-blind trial of quercetin in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoints: Number of enrolled participants per month at 13 months and Proportion eligible after screening. Planned start Sep 2022; status: withdrawn.
02
Drugs
quercetin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04258410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258410.